Skip to main content
Genscript Biotech Corporation logo

Genscript Biotech Corporation — Investor Relations & Filings

Ticker · 1548 ISIN · KYG3825B1059 LEI · 529900YIYUOJOXSAE372 HKEX Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2017-04-18 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 1548

About Genscript Biotech Corporation

http://www.genscript.com/investor-relat…

Genscript Biotech Corporation is a world-leading technology and service provider specializing in life science research and manufacturing. The company offers a comprehensive portfolio of services and products essential for fundamental life science research, translational biomedical research, and early drug discovery and development. Core offerings include custom synthesis of genes, peptides, proteins, and antibodies, alongside molecular cloning and oligonucleotide production. GenScript also provides Contract Development and Manufacturing Organization (CDMO) solutions for innovative therapies through its specialized subsidiaries. The corporation leverages biotechnology and AI-driven approaches to advance life science solutions.

Recent filings

Filing Released Lang Actions
PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS, DECLARATION OF FINAL DIVIDEND AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Genscript Biotech Corporation dated 19 April 2017, containing detailed proposals for the Annual General Meeting (AGM) scheduled for 31 May 2017. It includes notices about granting general mandates to issue and repurchase shares, re-election of retiring directors, declaration of final dividend, and the notice of the AGM itself. The document also contains a form of proxy and explanatory statements related to the AGM agenda items. The content is typical of a proxy circular or meeting circular sent to shareholders to inform them about the AGM agenda and solicit their votes. It is not a full annual report, earnings release, or financial statement, but rather a detailed meeting circular with proposals and notices for the AGM. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2017-04-18 English
ANNUAL REPORT 2016
Annual Report Classification · 100% confidence The document is titled '2016 Annual Report' and contains detailed sections typical of a full annual report, including corporate profile, financial highlights, five-year financial summary, chairman's statement, management discussion and analysis, directors and senior management, corporate governance report, environmental, social and governance report, independent auditor's report, and comprehensive financial statements. The content includes extensive financial data for the year ended December 31, 2016, and detailed narrative on business operations and performance. The length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K).
2017-04-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Genscript Biotech Corporation, detailing changes in issued share capital and share buybacks. It includes specific data on share issues, exercises of share options, and confirms compliance with listing rules regarding share repurchases. The content focuses on reporting changes in share capital and share buybacks, which aligns with announcements about share capital changes rather than a full financial report or earnings release. The document is regulatory in nature, providing detailed disclosure as required by the stock exchange rules, specifically related to share capital changes and repurchases. This fits the category of Share Issue/Capital Change (SHA). The document length (6239 characters) and detailed tabular data support it being a substantive disclosure rather than a brief announcement or certification. Therefore, the classification is SHA with high confidence.
2017-04-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2017
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 31/03/2017. The content focuses on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital changes and securities movements for a specific month. The document is not an annual or interim report, earnings release, or management discussion. It is a regulatory compliance report related to share capital movements, fitting best under Regulatory Filings (RNS) as it does not match more specific categories like Share Issue/Capital Change (SHA) because it covers a broad range of securities movements in a monthly return format, which is typical for regulatory filings to exchanges.
2017-04-07 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Genscript Biotech Corporation, detailing changes in issued share capital and share buybacks. It includes specific data on share issues and repurchases, referencing rules from the Hong Kong Stock Exchange Listing Rules. The content focuses on reporting changes in share capital and share buybacks, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is regulatory in nature, providing detailed disclosure of share capital changes and repurchases, fitting the category of Share Issue/Capital Change announcements. It is not a full report but a regulatory disclosure of capital changes.
2017-04-05 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Genscript Biotech Corporation, detailing changes in issued share capital and share buybacks. It includes specific data on share issues, exercises of share options, and repurchases, with references to Listing Rules of the Hong Kong Stock Exchange. The content focuses on reporting changes in share capital and share buybacks, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. The document is about disclosing share capital changes and repurchases, fitting the category of Share Issue/Capital Change (SHA). The document length is 6595 characters, which is sufficient to contain substantive data rather than just an announcement of a report. Therefore, the classification is SHA with high confidence.
2017-04-03 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.